RxDoctor Payments Data

Cynthia Burdick

Family · Beaufort, SCNPI 1700254497

Payments from drug & device makers

$1,784in general payments, 2019–2025

Across 95 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$233
  • Novo Nordisk$223
  • AbbVie$187
  • AstraZeneca$152
  • Aimmune Therapeutics, Inc.$125
  • Idorsia Pharmaceuticals US Inc$108
  • plus $756 from 18 others

What the payments were for

  • Food & beverage$1,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,784 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$41,375
Medicare patients
113
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$47,422
RexultiBrexpiprazole16$27,960
TrulicityDulaglutide12$12,286
JanuviaSitagliptin Phosphate16$11,681
Memantine Hcl153$4,039
Atorvastatin Calcium235$3,087
Midodrine Hcl36$2,350
Donepezil Hcl123$1,741
Levothyroxine Sodium180$1,604
Gabapentin71$1,550
Amlodipine Besylate155$1,420
Losartan Potassium112$1,405
Sertraline Hcl105$1,350
Omeprazole86$1,335
Escitalopram Oxalate96$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$47,422100 claims
Lilly USA, LLCTrulicity$92$12,28612 claims
MerckJanuvia$57$11,68116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Beaufort

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →